Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment of USD 100 million in 2018, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, RSS0343, intended to treat non-cystic fibrosis bronchiectasis (NCFB).
Understanding Non-Cystic Fibrosis Bronchiectasis (NCFB)
Non-cystic fibrotic bronchiectasis (NCFB) is a condition characterized by bronchial injury and permanent dilation due to various causes, including recurrent suppurative infections and chronic airway inflammation. The severity of clinical manifestations can vary, with symptoms such as chronic cough, excessive sputum production, intermittent hemoptysis, shortness of breath, and respiratory failure. NCFB is particularly common in Asian populations, and global incidence and prevalence rates have been on the rise in recent years. The current treatment goal for NCFB is to reduce acute exacerbations, improve disease symptoms, maintain or improve lung function, and enhance patients’ quality of life. Existing treatment plans primarily focus on symptom relief and short-term medication, with no long-term control or disease progression improvement drugs available.
RSS0343: A Potential New Treatment for NCFB
RSS0343 is an oral covalent reversible small molecule inhibitor that has not yet been approved for marketing domestically or internationally. It has demonstrated high inhibitory effects on its target activity in both in vivo and in vitro pharmacodynamics studies, exhibiting good selectivity. This new drug candidate from Reistone Biopharma holds promise for addressing the unmet needs in the long-term management and improvement of NCFB.-Fineline Info & Tech
